<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386671</url>
  </required_header>
  <id_info>
    <org_study_id>GlyMet01_13062011</org_study_id>
    <nct_id>NCT01386671</nct_id>
  </id_info>
  <brief_title>Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes</brief_title>
  <acronym>COMET</acronym>
  <official_title>Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy and safety of Metformin Glycinate versus
      Metformin Hydrochloride in metabolic control and inflammatory mediators in Mexican type 2
      diabetes patients, in a 12 months follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metformin glycinate salt is a new drug , which has better pharmacokinetic characteristics
      (better bioavailability and absorption) making a proper antihyperglycemic power without
      increasing the frequency of adverse effects. The drug has been tested in preclinical test
      with animals, in healthy subjects and in patients with type 2 diabetes; which showed that it
      has adequate antihyperglycemic effect. Now, its important to compare metformin glycinate and
      metformin hydrochloride for evaluate the relative antihyperglicemic power. In addition, a
      study with a larger number of patients improve the statistical power of the test to
      investigate the effects of these drugs on possible weight loss and lipid profile improve.
      Additionally, it will also explore the relative power of the two medications tested to modify
      inflammatory response mediators and oxidative stress have been associated with the incidence
      of cardiovascular disease in diabetes. This project was designed with the intent to answer
      the next question: What are the efficacy and safety of metformin glycinate dose of 2101.2
      mg/day (equivalent to 1700 mg/day metformin hydrochloride), compared with metformin
      hydrochloride in doses of 1700 mg/day for 12 months of treatment in patients with Type 2
      diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>12 months</time_frame>
    <description>HbA1c: Measured by electrophoresis of lacked total blood using Paragon system and Appraise reader 44800 (Beckman Instruments de Mexico).
Fasting Glucose: in serum using glucose oxidase technique with BM/Hitachi 704/911 automated analyzer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein (HDL)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density lipoprotein (LDL)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor-alpha (TNF-α)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistin</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1 beta (IL-1β)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malonylaldehyde</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dismutase superoxide</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin glycinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin glycinate is a new biguanide, for this study the dose administrated will be 1050.6 mg OD for a month, and 1050.6 mg BID for 11 moths.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin Hydrochloride is the biguanide most used, for this study the dose administrated will be 850 mg OD for a month, and 850 mg BID for 11 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin glycinate</intervention_name>
    <description>Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily</description>
    <arm_group_label>Metformin glycinate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin hydrochloride</intervention_name>
    <description>12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).</description>
    <arm_group_label>Metformin Hydrochloride</arm_group_label>
    <other_name>Predial</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes according ADA

          -  Less than a year of evolution since diagnosis

          -  Without antihyperglycemic pharmacological treatment

          -  HbA1c between 6.5% and 9.5%

          -  Stable weight during the last 6 months

          -  Body Mass Index ≥ 25 kg/m2 and &lt;35kg/m2.

          -  Blood pressure ≤ 130/80 mmHg

          -  Childbearing women under contraceptive treatment

          -  Signed Informed Consent Form

          -  Age from 18 to 70 years old

        Exclusion Criteria:

          -  Non-fulfilment treatment in the screening period

          -  Smoking up to 1 year before the initial examination

          -  Drugs or alcohol abuse

          -  Creatinine depuration estimated with MDRD formula using serum creatinine &lt; 90
             ml/min/1.72m2

          -  History of chronic liver disease, ALT or AST ≥ 2 times from the normal superior limit,
             or GGT ≥ 3 times from the normal superior limit.

          -  Chronic lung disease, that causes dyspnea equivalent to a functional class ≥3 (NYHA)or
             that requires oxygen supplementation.

          -  History or symptoms of coronary artery disease (CAD) or cerebrovascular disease (CVD).

          -  Drug treatment that interact with biguanides.

          -  Another chronic diseases that restricts survival or associated with chronic
             inflammation like: cancer, leukemia, lymphoma, erythematosus lupus, asthma, rheumatoid
             arthritis or infection for HIV.

          -  Pregnancy or positive pregnancy test in women under 50 years old or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels H Wacher, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMSS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad Antidiabética Integral</name>
      <address>
        <city>Mexico City</city>
        <state>AA</state>
        <zip>06600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus S.A. de C.V.</name>
      <address>
        <city>Mexico, city</city>
        <state>AA</state>
        <zip>03800</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion en Epidemiologia Clinica. UMAE Hospital de Especialidades Centro Medico Nacional Siglo XXI. Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de terapéutica experimental y clínica (INTEC)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Hermann LS, Scherstén B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med. 1994 Dec;11(10):953-60.</citation>
    <PMID>7895460</PMID>
  </reference>
  <reference>
    <citation>Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med. 2005 Apr;22(4):497-502.</citation>
    <PMID>15787679</PMID>
  </reference>
  <reference>
    <citation>Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010 Apr 14;303(14):1410-8. doi: 10.1001/jama.2010.405.</citation>
    <PMID>20388897</PMID>
  </reference>
  <reference>
    <citation>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558.</citation>
    <PMID>9742977</PMID>
  </reference>
  <reference>
    <citation>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.</citation>
    <PMID>18784090</PMID>
  </reference>
  <reference>
    <citation>Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009 Dec 3;339:b4731. doi: 10.1136/bmj.b4731.</citation>
    <PMID>19959591</PMID>
  </reference>
  <reference>
    <citation>Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008 Oct 27;168(19):2070-80. doi: 10.1001/archinte.168.19.2070. Review.</citation>
    <PMID>18955635</PMID>
  </reference>
  <results_reference>
    <citation>Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008 Oct 27;168(19):2088-94. doi: 10.1001/archinte.168.19.2088.</citation>
    <PMID>18955637</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>metformin glycinate</keyword>
  <keyword>metabolic control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

